Enliven Selling And Marketing Expenses from 2010 to 2025

ELVN Stock   21.08  0.16  0.76%   
Enliven Therapeutics Selling And Marketing Expenses yearly trend continues to be very stable with very little volatility. Selling And Marketing Expenses is likely to grow to about 22.9 M this year. During the period from 2010 to 2025, Enliven Therapeutics Selling And Marketing Expenses quarterly data regression pattern had sample variance of 101.4 T and median of  33,000. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
21.8 M
Current Value
22.9 M
Quarterly Volatility
10.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 100.9 M, Research Development of 84.8 M or Total Operating Expenses of 109.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.59. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Latest Enliven Therapeutics' Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of Enliven Therapeutics over the last few years. It is Enliven Therapeutics' Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Slightly volatile
   Selling And Marketing Expenses   
       Timeline  

Enliven Selling And Marketing Expenses Regression Statistics

Arithmetic Mean7,545,261
Geometric Mean364,735
Coefficient Of Variation133.45
Mean Deviation9,390,326
Median33,000
Standard Deviation10,069,026
Sample Variance101.4T
Range22.8M
R-Value0.86
Mean Square Error29.2T
R-Squared0.73
Significance0.000024
Slope1,809,016
Total Sum of Squares1520.8T

Enliven Selling And Marketing Expenses History

202522.9 M
202421.8 M
202018.9 M

About Enliven Therapeutics Financial Statements

Enliven Therapeutics investors utilize fundamental indicators, such as Selling And Marketing Expenses, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Selling And Marketing Expenses21.8 M22.9 M
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.